Xeris Biopharma Holdings, Inc. (NasdaqGS:XERS) is looking for acquisitions. Paul Edick, Chairman and Chief Executive Officer said, "We are focused on potential acquisitions in order to add to our pipeline and most importantly, our commercial business, through acquisition, and those partnerships allow us to generate incremental revenue to do all of the above".
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.255 USD | +1.12% | +16.84% | -4.04% |
May. 30 | Sector Update: Health Care Stocks Higher in Afternoon Trading | MT |
May. 30 | Xeris Biopharma Says Potential Levothyroxine Injection Preferred Over Oral Formulation; Shares Rise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.04% | 334M | |
+40.73% | 739B | |
+31.07% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+14.91% | 240B | |
+9.33% | 210B | |
-5.24% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings Seeks Acquisitions